Mount Sinai has become one of the few health systems in the nation to offer a new minimally invasive procedure to treat noncancerous thyroid nodules. The procedure, called radiofrequency ablation (RFA), offers eligible patients a quicker recovery and minimal scarring, with preservation of surrounding healthy thyroid tissue.
Catherine Sinclair, MD, Associate Professor of Otolaryngology, Icahn School of Medicine at Mount Sinai, and Director of Head and Neck Surgery at Mount Sinai West, performed Mount Sinai’s first RFA procedures in August 2019. “I truly believe this procedure will change management and improve outcomes for a subset of patients with symptomatic, noncancerous thyroid nodules,” says Dr. Sinclair. Mount Sinai is also a leader in offering ethanol ablation, a similarly noninvasive procedure.
Thyroid nodules are masses composed of tissue or fluid, or both, that form in the thyroid, a butterfly-shaped gland near the front of the lower neck. Nodules are very common, estimated to be present in 50 percent of those aged 50 and older. More than 95 percent are noncancerous, and most require no intervention. “For noncancerous thyroid nodules, we intervene surgically or with RFA only if the nodules are very large or symptomatic,” Dr. Sinclair explains. “Symptoms may include neck discomfort, neck swelling, difficulty swallowing or breathing, or changes in the voice from pressure on the nerve to the larynx.”
Although invasive surgery is the most common management option, RFA is an important consideration for patients with noncancerous nodules, Dr. Sinclair says. With RFA, surgeons use guided ultrasound to deliver radiofrequency current to heat the thyroid nodule, which shrinks significantly over the next several months. Patients who undergo RFA can return to normal activity the next day and exercise normally within several days, compared with several weeks for patients who undergo standard thyroid surgery. In addition, RFA targets only the nodule, compared with traditional surgery, which usually removes one side of the thyroid and makes lifelong hormone supplements necessary for 20 to 30 percent of patients.
“Radiofrequency ablation for thyroid nodules has been performed in Korea for over a decade and throughout Europe, and their outcomes are excellent. The published data show nodule shrinkage rates of more than 80 percent with RFA that is maintained over years of follow-up,” says Dr. Sinclair, who learned RFA from a pioneer in the field, Jung Hwan Baek, MD, PhD, at the Asan Medical Center in Seoul, South Korea.
Dr. Sinclair also has developed a continuous laryngeal reflex monitoring system that is used during RFA to prevent vocal cord damage and hoarseness, which are potential risks during both RFA and standard surgery. In the system, nerve fibers within the neck are continuously stimulated to check their function, allowing surgeons to quickly take preventive measures against injury. This innovative method does not require a neck incision and is the only monitoring technique available for noninvasive procedures such as RFA.
Mount Sinai is one of the few health systems in the region to offer ethanol ablation. In that procedure, an alcohol solution is injected into thyroid nodules, killing cells and causing the masses to slowly shrink. The procedure leaves only a small scar and is performed in the office with local anesthesia. Dr. Sinclair says ethanol ablation may be more effective than RFA for fluid-filled thyroid cysts, and RFA is a better noninvasive choice for large, solid nodules. A combination of both procedures can be used for cystic/solid lesions. Ethanol ablation is performed at the Mount Sinai Thyroid Center at Union Square by its Director, Maria Brito, MD, Assistant Professor of Medicine (Endocrinology, Diabetes and Bone Disease), Icahn School of Medicine; and Michael Via, MD, Associate Professor of Medicine (Endocrinology, Diabetes and Bone Disease), Icahn School of Medicine; and by Dr. Sinclair at Mount Sinai West.
“The procedures will not necessarily eliminate the nodule completely, and patients will still need to have ultrasound follow-ups to monitor the nodule,” Dr. Brito says. “But in appropriate cases, they are a terrific option. They make it very easy for
the patient.”